Shots:

• The company starts enrolling patients in the P-III MYLIGHT study to evaluate the safety and efficacy of biosimilar aflibercept vs Eylea in patients with nAMD for 48wks. The study is expected to enroll 460 patients across 20 countries
• The study is a part of a biosimilar development program that includes analytical- pre/ clinical data. The study focuses to confirm the efficacy & safety of biosimilar aflibercept to the Eylea
• The company has eight marketed biosimilar medicines globally and 15+ molecules in the pipeline and focuses to expand the access to affordable biologics

  Ref: Sandoz | Image: Sandoz